Compare ARVN & DGICB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ARVN | DGICB |
|---|---|---|
| Founded | 2015 | 1986 |
| Country | United States | United States |
| Employees | N/A | 851 |
| Industry | Biotechnology: Pharmaceutical Preparations | Property-Casualty Insurers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 658.2M | 654.6M |
| IPO Year | 2018 | N/A |
| Metric | ARVN | DGICB |
|---|---|---|
| Price | $8.95 | $19.15 |
| Analyst Decision | Buy | |
| Analyst Count | 19 | 0 |
| Target Price | ★ $15.05 | N/A |
| AVG Volume (30 Days) | ★ 858.9K | 473.0 |
| Earning Date | 05-04-2026 | 04-30-2026 |
| Dividend Yield | N/A | ★ 3.34% |
| EPS Growth | ★ 58.84 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $262,600,000.00 | N/A |
| Revenue This Year | N/A | $2.26 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $8.06 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $6.06 | $13.84 |
| 52 Week High | $14.22 | $20.30 |
| Indicator | ARVN | DGICB |
|---|---|---|
| Relative Strength Index (RSI) | 37.05 | 53.75 |
| Support Level | $8.72 | $15.35 |
| Resistance Level | $10.18 | $19.90 |
| Average True Range (ATR) | 0.47 | 0.36 |
| MACD | 0.00 | -0.08 |
| Stochastic Oscillator | 28.82 | 76.84 |
Arvinas Inc is a clinical-stage biotechnology company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. The company is using its PROteolysis TArgeting Chimera, a protein degradation platform, to develop therapeutics designed to harness the body's own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. Its clinical development program includes various product candidates such as ARV-102, ARV-806, ARV-393, ARV-027, and vepdegestrant, in their different stages of development, being developed to target certain harmful proteins causing oncology and neurology-related diseases.
Donegal Group Inc is an insurance holding company whose insurance subsidiaries and affiliates offer property and casualty insurance in 21 Mid-Atlantic, Midwestern, Southern, and Southwestern states. It includes three segments: Investments Function, Commercial Lines of Insurance, and Personal Lines of Insurance. The majority of revenue is from the commercial Lines segment. The commercial Lines segment consists mainly of commercial automobile, commercial multi-peril, and workers' compensation policies.